0–2.5 mg/kg for Caucasian. It has been reported that the lower dose (1.0–2.0 mg/kg) in some Asian countries was as effective as the standard dose. In the present study buy STA-9090 we analyzed the efficacy of <1.0 mg/kg AZA in maintaining remission for Chinese patients. Methods: The clinical data of all CD were reviewed from 1993 to December 2012. The patients

who initiated AZA treatment and were followed for ≥2 years with complete medical data were included. We divided the patients into two groups according to their initial dose: <1.0 mg/kg group and 1.0–2.0 mg/kg group. Results: Among 77 patients, 39 (50.6%) maintained remission with <1.0 mg/kg and 38 (49.4%) with 1.0–2.0 mg/kg of AZA. The mean dose of <1.0 mg/kg group continued <1.0 mg/kg and significant lower than 1.0–2.0 mg/kg group at 6, 12 and 24 months, even if the

doses were adjusted according to the efficacy and tolerance. The remission rate of <1.0 mg/kg group was significant higher than 1.0–2.0 mg/kg group (P = 0.025). Male, INCB018424 manufacturer older patients, heavier body weight and L1 location were associated with <1.0 mg/kg AZA. Adverse events observed in 31 of 77 patients (40.3%), there was no significant difference in occurrence of adverse events or leucopenia between two groups. Conclusion: The low dose AZA (<1.0 mg/kg) in maintaining remission was effective as 1.0–2.0 mg/kg among Chinese patients with CD. Key Word(s): 1. <1.0 mg/kg AZA; 2. maintain remission; 3. Crohn's disease; 4. Chinese patients; Presenting Author: YOULIAN ZHOU Additional MCE公司 Authors: YAN HE, TING ZHANG, ZHONGQIU WANG, SHAOHENG ZHANG, BO JIANG, YE CHEN Corresponding Author: YE CHEN Affiliations: Nanfang hospital; Department of Environmental Health, School of Public Health and Tropical Medicine Objective: The Infliximab have dramatically improved the treatment in Crohn’s disease

(CD). However, loss of response to Infliximab is an emerging clinical problem and the prospective studies of intestinal flora on anti-TNFα treatment are relatively unexplored. The aim of this study was to investigate effects of infliximab treatment on gut microbiome in patients with CD. Methods: 18 patients with CD (13 with sustained response, 5 with replase) treated with Infliximab (5 mg/kg at weeks 0, 2, and 6 and then every eight weeks) and 8 healthy controls was recruited. The fecal microbial community was analyzed by sequencing 16S rRNA V4 tags on Illumina Miseq platform followed by real-time quantitative polymerase chain reaction. Results: Dramatic shifts were observed both before and during infliximab treatment in both bacterial diversity and richness, while the microbial communities of health control subjects were relatively stable over time. Campared with sustained response group, the proportions of both phylum Proteobacteria and Bacteroidetes were increased in the replase group (P < 0.05). Positive correlations were observed between Veillonellaceae and disease duration (R = 0.4099, P = 0.014) or CRP (R = 0.4049, P = 0.